



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/509,255	05/23/2005	Jean Fioramonti	045636-5081	1258
9629 7590 08/24/2007 MORGAN LEWIS & BOCKIUS LLP 1111 PENNSYLVANIA AVENUE NW WASHINGTON, DC 20004			EXAMINER TONGUE, LAKIA J	
			ART UNIT 1645	PAPER NUMBER
			MAIL DATE 08/24/2007	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Sally Teng on August 15, 2007.

The application has been amended as follows:

To the specification:

After page 8, line 15, the following was inserted:

Brief Description of Drawings

Figure 1 shows myeloperoxidase (MPO) activity (MPO U/g of protein) in rats after treatment with SNP.

Figure 2 shows MPO activity (MPO U/g of protein) in rats after treatment with *L. farciminis*.

Figure 3 shows macroscopic lesion scores in rats after treatment with SNP.

Figure 4 shows macroscopic lesion scores in rats after treatment with *L. farciminis*.

Figure 5 shows the curative effect of *L. farciminis* on colonic inflammation.

Figure 6 shows the effect of treatment with *L. farciminis* under basal conditions, on pain during colorectal distension.

Art Unit: 1645

Figure 7 shows the effect of treatment with *L. farciminis* under inflammatory conditions, on pain during colorectal distention.

Figure 8 shows the effect of treatment with *L. farciminis* under stress conditions, on pain during colorectal distension.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance".

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lakia J. Tongue whose telephone number is 571-272-2921. The examiner can normally be reached on Monday-Friday 8-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffery Siew can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO

Application/Control Number: 10/509,255

Page 4

Art Unit: 1645

Customer Service Representative or access to the automated information system, call
800-786-9199 (IN USA OR CANADA) or 571-272-1000.

LJT

8/16/07

A handwritten signature in black ink, appearing to read "Robert Zeman". The signature is fluid and cursive, with the first name "Robert" and last name "Zeman" clearly distinguishable.

ROBERT A. ZEMAN
PRIMARY EXAMINER